ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT
The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-...
Gespeichert in:
| Veröffentlicht in: | The American journal of tropical medicine and hygiene 2005-11, Vol.73 (5 suppl), p.16-24 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | 5 suppl |
| container_start_page | 16 |
| container_title | The American journal of tropical medicine and hygiene |
| container_volume | 73 |
| creator | VALDERRAMA-AGUIRRE, AUGUSTO QUINTERO, GUSTAVO GOMEZ, ANDRES CASTELLANOS, ALEJANDRO PEREZ, YOBANA MENDEZ, FABIAN AREVALO-HERRERA, MYRIAM HERRERA, SOCRATES |
| description | The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] = 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI = 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing. |
| doi_str_mv | 10.4269/ajtmh.2005.73.16 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68807517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68807517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-ae67f9f9612f3bf073b4a0b72c08d170802c5180eda613125d3d29636acbba4e3</originalsourceid><addsrcrecordid>eNqFkc9v0zAYhi0EYt3gzgn5xAGR4s9J7ISbydJhKb-0JhE7WU7q0E7JWpJW1fjrcWmlHTlZn_S8z-dPL0IfgMw9ysKv-nE_rOeUEH_O3TmwV2gGHmcOMM9_jWaEEOqEzOVX6HqaHgmBgAK8RVfAaAic0Rn6I7JS3sWZjGT58AXLNK2y_GUW2S0u7vMyjkpZxzheLGQkogecL3CRiGWa38oqxbWsxU-cLgvARW1_k3zDAhc2Zd0iwalIxL0UuBZRJLMYL6vvVSbLd-hNp_vJvL-8N6haxGX0w0nyO7slcVqPw97RhvEu7EIGtHObjnC38TRpOG1JsAJOAkJbHwJiVpqBC9RfuStqj2a6bRrtGfcGfTp7d-P298FMezVsptb0vX4y28OkWBAQ7gP_Lwgh55T51ILkDLbjdppG06nduBn0-KyAqFMx6l8x6lSM4q4CZiMfL-5DM5jVS-DShAU-n4H15tf6uBmNmgbd9xYHdTwercVX02G360-2v8-Ujtc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19772652</pqid></control><display><type>article</type><title>ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>VALDERRAMA-AGUIRRE, AUGUSTO ; QUINTERO, GUSTAVO ; GOMEZ, ANDRES ; CASTELLANOS, ALEJANDRO ; PEREZ, YOBANA ; MENDEZ, FABIAN ; AREVALO-HERRERA, MYRIAM ; HERRERA, SOCRATES</creator><creatorcontrib>VALDERRAMA-AGUIRRE, AUGUSTO ; QUINTERO, GUSTAVO ; GOMEZ, ANDRES ; CASTELLANOS, ALEJANDRO ; PEREZ, YOBANA ; MENDEZ, FABIAN ; AREVALO-HERRERA, MYRIAM ; HERRERA, SOCRATES</creatorcontrib><description>The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] = 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI = 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2005.73.16</identifier><identifier>PMID: 16291762</identifier><language>eng</language><publisher>United States: ASTMH</publisher><subject>Amino Acid Sequence ; Animals ; Antibodies, Protozoan - blood ; Antigens, Protozoan - chemistry ; Antigens, Protozoan - genetics ; Antigens, Protozoan - immunology ; Antigens, Protozoan - metabolism ; Antigens, Surface - chemistry ; Antigens, Surface - genetics ; Antigens, Surface - immunology ; Antigens, Surface - metabolism ; Aotus ; Cebidae ; Colombia - epidemiology ; Cross-Sectional Studies ; Escherichia coli ; Escherichia coli - genetics ; Escherichia coli - metabolism ; Humans ; Immunization ; Immunoglobulin G - blood ; Malaria Vaccines - administration & dosage ; Malaria Vaccines - genetics ; Malaria Vaccines - immunology ; Malaria, Vivax - epidemiology ; Malaria, Vivax - immunology ; Malaria, Vivax - prevention & control ; Merozoite Surface Protein 1 - chemistry ; Mice ; Mice, Inbred BALB C ; Molecular Sequence Data ; Plasmodium ; Plasmodium falciparum ; Plasmodium vivax ; Plasmodium vivax - immunology ; Plasmodium vivax - pathogenicity ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; Recombinant Proteins - metabolism ; Seroepidemiologic Studies</subject><ispartof>The American journal of tropical medicine and hygiene, 2005-11, Vol.73 (5 suppl), p.16-24</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-ae67f9f9612f3bf073b4a0b72c08d170802c5180eda613125d3d29636acbba4e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16291762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VALDERRAMA-AGUIRRE, AUGUSTO</creatorcontrib><creatorcontrib>QUINTERO, GUSTAVO</creatorcontrib><creatorcontrib>GOMEZ, ANDRES</creatorcontrib><creatorcontrib>CASTELLANOS, ALEJANDRO</creatorcontrib><creatorcontrib>PEREZ, YOBANA</creatorcontrib><creatorcontrib>MENDEZ, FABIAN</creatorcontrib><creatorcontrib>AREVALO-HERRERA, MYRIAM</creatorcontrib><creatorcontrib>HERRERA, SOCRATES</creatorcontrib><title>ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] = 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI = 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antigens, Protozoan - chemistry</subject><subject>Antigens, Protozoan - genetics</subject><subject>Antigens, Protozoan - immunology</subject><subject>Antigens, Protozoan - metabolism</subject><subject>Antigens, Surface - chemistry</subject><subject>Antigens, Surface - genetics</subject><subject>Antigens, Surface - immunology</subject><subject>Antigens, Surface - metabolism</subject><subject>Aotus</subject><subject>Cebidae</subject><subject>Colombia - epidemiology</subject><subject>Cross-Sectional Studies</subject><subject>Escherichia coli</subject><subject>Escherichia coli - genetics</subject><subject>Escherichia coli - metabolism</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunoglobulin G - blood</subject><subject>Malaria Vaccines - administration & dosage</subject><subject>Malaria Vaccines - genetics</subject><subject>Malaria Vaccines - immunology</subject><subject>Malaria, Vivax - epidemiology</subject><subject>Malaria, Vivax - immunology</subject><subject>Malaria, Vivax - prevention & control</subject><subject>Merozoite Surface Protein 1 - chemistry</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Molecular Sequence Data</subject><subject>Plasmodium</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium vivax</subject><subject>Plasmodium vivax - immunology</subject><subject>Plasmodium vivax - pathogenicity</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>Recombinant Proteins - metabolism</subject><subject>Seroepidemiologic Studies</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9v0zAYhi0EYt3gzgn5xAGR4s9J7ISbydJhKb-0JhE7WU7q0E7JWpJW1fjrcWmlHTlZn_S8z-dPL0IfgMw9ysKv-nE_rOeUEH_O3TmwV2gGHmcOMM9_jWaEEOqEzOVX6HqaHgmBgAK8RVfAaAic0Rn6I7JS3sWZjGT58AXLNK2y_GUW2S0u7vMyjkpZxzheLGQkogecL3CRiGWa38oqxbWsxU-cLgvARW1_k3zDAhc2Zd0iwalIxL0UuBZRJLMYL6vvVSbLd-hNp_vJvL-8N6haxGX0w0nyO7slcVqPw97RhvEu7EIGtHObjnC38TRpOG1JsAJOAkJbHwJiVpqBC9RfuStqj2a6bRrtGfcGfTp7d-P298FMezVsptb0vX4y28OkWBAQ7gP_Lwgh55T51ILkDLbjdppG06nduBn0-KyAqFMx6l8x6lSM4q4CZiMfL-5DM5jVS-DShAU-n4H15tf6uBmNmgbd9xYHdTwercVX02G360-2v8-Ujtc</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>VALDERRAMA-AGUIRRE, AUGUSTO</creator><creator>QUINTERO, GUSTAVO</creator><creator>GOMEZ, ANDRES</creator><creator>CASTELLANOS, ALEJANDRO</creator><creator>PEREZ, YOBANA</creator><creator>MENDEZ, FABIAN</creator><creator>AREVALO-HERRERA, MYRIAM</creator><creator>HERRERA, SOCRATES</creator><general>ASTMH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>F1W</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT</title><author>VALDERRAMA-AGUIRRE, AUGUSTO ; QUINTERO, GUSTAVO ; GOMEZ, ANDRES ; CASTELLANOS, ALEJANDRO ; PEREZ, YOBANA ; MENDEZ, FABIAN ; AREVALO-HERRERA, MYRIAM ; HERRERA, SOCRATES</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-ae67f9f9612f3bf073b4a0b72c08d170802c5180eda613125d3d29636acbba4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antigens, Protozoan - chemistry</topic><topic>Antigens, Protozoan - genetics</topic><topic>Antigens, Protozoan - immunology</topic><topic>Antigens, Protozoan - metabolism</topic><topic>Antigens, Surface - chemistry</topic><topic>Antigens, Surface - genetics</topic><topic>Antigens, Surface - immunology</topic><topic>Antigens, Surface - metabolism</topic><topic>Aotus</topic><topic>Cebidae</topic><topic>Colombia - epidemiology</topic><topic>Cross-Sectional Studies</topic><topic>Escherichia coli</topic><topic>Escherichia coli - genetics</topic><topic>Escherichia coli - metabolism</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunoglobulin G - blood</topic><topic>Malaria Vaccines - administration & dosage</topic><topic>Malaria Vaccines - genetics</topic><topic>Malaria Vaccines - immunology</topic><topic>Malaria, Vivax - epidemiology</topic><topic>Malaria, Vivax - immunology</topic><topic>Malaria, Vivax - prevention & control</topic><topic>Merozoite Surface Protein 1 - chemistry</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Molecular Sequence Data</topic><topic>Plasmodium</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium vivax</topic><topic>Plasmodium vivax - immunology</topic><topic>Plasmodium vivax - pathogenicity</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>Recombinant Proteins - metabolism</topic><topic>Seroepidemiologic Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VALDERRAMA-AGUIRRE, AUGUSTO</creatorcontrib><creatorcontrib>QUINTERO, GUSTAVO</creatorcontrib><creatorcontrib>GOMEZ, ANDRES</creatorcontrib><creatorcontrib>CASTELLANOS, ALEJANDRO</creatorcontrib><creatorcontrib>PEREZ, YOBANA</creatorcontrib><creatorcontrib>MENDEZ, FABIAN</creatorcontrib><creatorcontrib>AREVALO-HERRERA, MYRIAM</creatorcontrib><creatorcontrib>HERRERA, SOCRATES</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VALDERRAMA-AGUIRRE, AUGUSTO</au><au>QUINTERO, GUSTAVO</au><au>GOMEZ, ANDRES</au><au>CASTELLANOS, ALEJANDRO</au><au>PEREZ, YOBANA</au><au>MENDEZ, FABIAN</au><au>AREVALO-HERRERA, MYRIAM</au><au>HERRERA, SOCRATES</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>73</volume><issue>5 suppl</issue><spage>16</spage><epage>24</epage><pages>16-24</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><abstract>The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] = 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI = 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.</abstract><cop>United States</cop><pub>ASTMH</pub><pmid>16291762</pmid><doi>10.4269/ajtmh.2005.73.16</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9637 |
| ispartof | The American journal of tropical medicine and hygiene, 2005-11, Vol.73 (5 suppl), p.16-24 |
| issn | 0002-9637 1476-1645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68807517 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Amino Acid Sequence Animals Antibodies, Protozoan - blood Antigens, Protozoan - chemistry Antigens, Protozoan - genetics Antigens, Protozoan - immunology Antigens, Protozoan - metabolism Antigens, Surface - chemistry Antigens, Surface - genetics Antigens, Surface - immunology Antigens, Surface - metabolism Aotus Cebidae Colombia - epidemiology Cross-Sectional Studies Escherichia coli Escherichia coli - genetics Escherichia coli - metabolism Humans Immunization Immunoglobulin G - blood Malaria Vaccines - administration & dosage Malaria Vaccines - genetics Malaria Vaccines - immunology Malaria, Vivax - epidemiology Malaria, Vivax - immunology Malaria, Vivax - prevention & control Merozoite Surface Protein 1 - chemistry Mice Mice, Inbred BALB C Molecular Sequence Data Plasmodium Plasmodium falciparum Plasmodium vivax Plasmodium vivax - immunology Plasmodium vivax - pathogenicity Recombinant Proteins - genetics Recombinant Proteins - immunology Recombinant Proteins - metabolism Seroepidemiologic Studies |
| title | ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANTIGENICITY,%20IMMUNOGENICITY,%20AND%20PROTECTIVE%20EFFICACY%20OF%20PLASMODIUM%20VIVAX%20MSP1%20PV200L:%20A%20POTENTIAL%20MALARIA%20VACCINE%20SUBUNIT&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=VALDERRAMA-AGUIRRE,%20AUGUSTO&rft.date=2005-11-01&rft.volume=73&rft.issue=5%20suppl&rft.spage=16&rft.epage=24&rft.pages=16-24&rft.issn=0002-9637&rft.eissn=1476-1645&rft_id=info:doi/10.4269/ajtmh.2005.73.16&rft_dat=%3Cproquest_cross%3E68807517%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19772652&rft_id=info:pmid/16291762&rfr_iscdi=true |